Cargando…
DUSP1 Is a Novel Target for Enhancing Pancreatic Cancer Cell Sensitivity to Gemcitabine
Pancreatic ductal adenocarcinoma (PDAC) is a deadly cancer with a poor prognosis that is characterized by excessive mitogenic pathway activation and marked chemoresistance to a broad spectrum of chemotherapeutic drugs. Dual specificity protein phosphatase 1 (DUSP1) is a key negative regulator of mit...
Autores principales: | Liu, Fang, Gore, A. Jesse, Wilson, Julie L., Korc, Murray |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3883684/ https://www.ncbi.nlm.nih.gov/pubmed/24409315 http://dx.doi.org/10.1371/journal.pone.0084982 |
Ejemplares similares
-
Correction: DUSP1 Is a Novel Target for Enhancing Pancreatic Cancer Cell Sensitivity to Gemcitabine
Publicado: (2014) -
Expression of Concern: DUSP1 Is a Novel Target for Enhancing Pancreatic Cancer Cell Sensitivity to Gemcitabine
Publicado: (2020) -
Angiogenic gene signature in human pancreatic cancer correlates with TGF-beta and inflammatory transcriptomes
por: Craven, Kelly E., et al.
Publicado: (2015) -
Integrated stress response is critical for gemcitabine resistance in pancreatic ductal adenocarcinoma
por: Palam, L R, et al.
Publicado: (2015) -
Interferon-beta enhances sensitivity to gemcitabine in pancreatic cancer
por: Blaauboer, Amber, et al.
Publicado: (2020)